Kidney Disease

Zemdri Now Available for the Treatment of Complicated UTI, Pyelonephritis

By July 20, 2018

Zemdri carries a Boxed Warning describing reports of nephrotoxicity, ototoxicity, and neuromuscular blockade, as well as fetal harm if administered during pregnancy.

Trulicity Labeling Updated to Include Data on T2D Patients With CKD

By July 19, 2018

In the AWARD-7 trial, patients who received Trulicity 0.75mg or 1.5mg in combination with mealtime insulin lispro achieved similar glycemic control with weight loss vs patients who received traditional basal-bolus insulin.

Canagliflozin Trial for T2D With CKD Stopped Early Due to Positive Results

By July 17, 2018

A clinical trial assessing canagliflozin (Invokana; Janssen) as an addition to standard-of-care in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) has been stopped early after meeting its pre-specified efficacy criteria.

FDA Permits Marketing of Devices to Create Arteriovenous Fistula

July 05, 2018

Two devices designed to create arteriovenous fistula in patients with CKD in need of hemodialysis

Nitric Oxide Cuts Kidney Injury After Long Cardiac Surgery

July 02, 2018

Reduced kidney injury, better kidney function seen after prolonged cardiopulmonary bypass

Dulaglutide Assessed in T2D Patients With Chronic Kidney Disease

By June 20, 2018

In AWARD-7, eligible patients (N=577) were randomized to receive dulaglutide 1.5mg once-weekly (N=193), dulaglutide 0.75mg (N=190) once-weekly, or insulin glargine daily (N=194), all in combination with insulin lispro, for 52 weeks. HbA1c at 26 weeks with a 0.4% non-inferiority margin was designated as the primary outcome, while secondary outcomes included eGFR and urine albumin-to-creatinine ratio.

Many AKI Reports in FAERS Linked to Drugs Not Recognized as Nephrotoxic

By June 12, 2018

According to the authors, this is the first study to identify medications most commonly reported for a specific adverse reaction using this database.

More Rapid Decline in Kidney Function for Diagnosed Diabetes

June 08, 2018

Much steeper decline in adjusted mean eGFR for those with diagnosed diabetes versus those without

Positive Results Announced for First-in-Class Metabolic Acidosis Treatment

By June 05, 2018

After 12 weeks, 59.2% of patients treated with the study drug saw an increased blood bicarbonate of ≥4mEq/L or achieved a level in the normal range (22 to 29mEq/L) vs 22.5% of patients in the placebo group (primary endpoint; P <.0001).

Raviten Gets Fast Track Status for Intradialytic Hypotension Management

By May 29, 2018

Intradialytic hypotension is a common complication of hemodialysis and can lead to increased morbidity and mortality among patients with end-stage renal disease.

Hyperkalemia Treatment Lokelma Gets FDA Approval

By May 21, 2018

Lokelma is a non-absorbed zirconium silicate that preferentially captures potassium in exchange for hydrogen and sodium.

Undisclosed Lab Result Leads to Lawsuit After Patient's Death

By May 02, 2018

Dr P's expert testified that there was nothing to treat or to tell the patient about.

First FDA-Approved Treatment for X-Linked Hypophosphatemia Launched

By April 30, 2018

Crysvita, a recombinant fully human monoclonal IgG1 antibody, works by blocking fibroblast growth factor 23 (FGF23), a hormone that causes phosphate urinary excretion and suppresses vitamin D production by the kidney.

Jynarque Approved to Slow Kidney Function Decline in Patients With ADPKD

By April 25, 2018

The efficacy of tolvaptan was demonstrated in two pivotal trials, lasting one year and three years, respectively.

Carvedilol vs Metoprolol: Mortality Risk Examined Among Hemodialysis Patients

By April 18, 2018

Results showed that compared to metoprolol, those who initiated carvedilol had a greater all-cause (HR, 1.08; 95% CI,1.02-1.16) and cardiovascular mortality (HR, 1.18; 95% CI, 1.08-1.29).

Crysvita Approved for the Treatment of X-Linked Hypophosphatemia

By April 17, 2018

Crysvita is an antibody that blocks fibroblast growth factor 23 (FGF23), a hormone that causes phosphate urinary excretion and suppresses active vitamin D production by the kidney.

Sacubitril/Valsartan May Help Preserve Kidney Function in Patients With HFrEF

By April 16, 2018

Compared with the enalapril-treated group, those treated with sacubitril/valsartan were found to have significantly slower kidney decline (-1.3 vs -1.8mL/min/1.73m2 per year; P<0.0001).

Canagliflozin May Improve Renal Outcomes in Patients With T2D

By April 12, 2018

The renal protective benefit was seen in patients with both reduced (eGFR <60mL/min/1.73m2) and preserved (eGFR ≥60mL/min/1.73m2) renal function.

Add-On Antihypertensives Compared in Patients With Diabetes on ACEIs, ARBs

By March 28, 2018

The composite significant kidney event end point was defined as the first occurrence of ≥30% decline in eGFR to an eGFR <60mL/min/1.73m2, initiation of dialysis or kidney transplant.

Dapagliflozin Evaluated in Patients With T2D and Moderate Renal Impairment

By March 20, 2018

Farxiga is a sodium-glucose co-transporter 2 (SGLT2) inhibitor currently indicated as an adjunct to diet and exercise to improve glycemic control in adults with T2D mellitus.

CDC: Acute Kidney Injury Hospitalization Rates Examined in the U.S.

By March 16, 2018

For the report, AKI was defined as the occurrence of at least 1 diagnostic code 584 (acute renal failure) or the occurrence of at least 1 procedure code of 39.95 (hemodialysis) or 54.98 (peritoneal dialysis).

Regional variation in CT imaging is associated with nephrectomy risk

January 03, 2018

Regional variation in cumulative risk of an individual having a chest or abdominal CT in the United States was positively correlated with the risk of both total and partial nephrectomy, as well as any renal procedure (including renal ablation).

Outcomes after left ventricular assist device implantation significantly worse for those with end-stage renal disease

January 03, 2018

Patients with end-stage renal disease (ESRD) have significantly worse survival outcomes following left ventricular assist device (LVAD) implantation compared to recipients without ESRD.

Hospital Admissions for <i>C. difficile</i> Infection and Acute Kidney Injury Increasing

December 13, 2017

Despite increase in admissions, inpatient mortality improved from 2003 to 2012

Tolvaptan Slows Loss of Renal Function in Later-Stage ADPKD

November 06, 2017

Reduction in decline in eGFR for patients with later-stage autosomal dominant polycystic kidney disease

Lixivaptan Gets Orphan Drug Status for Autosomal Dominant PKD

By October 05, 2017

Lixivaptan is a potent, selective vasopressin V2 receptor antagonist which has been found to delay the progression of an autosomal dominant form of polycystic kidney disease.

Sleep Duration, Quality Tied to Chronic Kidney Disease Progression

September 15, 2017

Shorter sleep duration, greater sleep fragmentation linked to greater decline in eGFR

Intensive Blood Pressure Control Linked to Increased CKD Risk

September 08, 2017

However, cardiovascular events, all-cause mortality risk decrease with intensive blood pressure lowering

Acute Kidney Injury Seen in Marathon Runners

March 29, 2017

Injury and repair biomarker levels suggest structural damage to renal tubules

Orphan Drug Status Granted for C3 Glomerulopathy Treatment

By March 22, 2017

Patients with C3G experience progressive deterioration in renal function, ultimately leading to renal failure requiring dialysis and kidney transplant, if left untreated.